ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

Gene Ontology: tool for the unification of biology

Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206 · see citing works

The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease

Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257 · see citing works

An oestrogen-receptor-α-bound human chromatin interactome

Fullwood, M. J., Liu, M. H., Pan, Y. F., Liu, J., Han, X., Mohamed, Y. B., Orlov, Y. L., Velkov, S., Ho, A., Poh, H. M., et al. (2009) · Nature · doi:10.1038/nature08497 · Cited by 1,728 · see citing works

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674 · see citing works

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · see citing works

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398 · see citing works

Genome-wide analysis of estrogen receptor binding sites

Carroll, J. S., Meyer, C. A., Song, J. S., Li, W., Geistlinger, T., Eeckhoute, J., Brodsky, A. S., Keeton, E. K., Fertuck, K. C., Hall, G., et al. (2006) · Nature Genetics · doi:10.1038/ng1901 · Cited by 1,368 · see citing works

Biological determinants of endocrine resistance in breast cancer

Musgrove, E. A., & Sutherland, R. L. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2713 · Cited by 1,254 · see citing works

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou, J., Massarweh, S., Osborne, C., Wakeling, A., Ali, S., Weiss, H., & Schiff, R. (2004) · Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,236 · see citing works

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · see citing works

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

Williams, N. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 918 · see citing works

Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer

Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 897 · see citing works

Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α

Campbell, R., Bhat-Nakshatri, P., Patel, N., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 880 · see citing works

FOXA1 is a key determinant of estrogen receptor function and endocrine response

Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D., & Carroll, J. S. (2010) · Nature Genetics · doi:10.1038/ng.730 · Cited by 847 · see citing works

Repression of the Interleukin-6 Promoter by Estrogen Receptor Is Mediated by NF-κB and C/EBPβ

Stein, B., & Yang, M. X. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.4971 · Cited by 697 · see citing works

Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer

Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A. I., A’Hern, R., Salter, J., DETRE, S. I., Hills, M., & Walsh, G. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk020 · Cited by 665 · see citing works

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636 · see citing works

Mechanisms of Androgen-Refractory Prostate Cancer

Debes, J. D., & Tindall, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048178 · Cited by 558 · see citing works

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer

Miller, T. W., Hennessy, B. T., Gonzalez-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., Garcı́a-Echeverrı́a, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 555 · see citing works

Cell cycle regulation of the human cdc2 gene.

Dalton, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05231.x · Cited by 382 · see citing works

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer

Holst, F., Stahl, P. R., Ruiz, C. F., Hellwinkel, O., Jehan, Z., Wendland, M., Lebeau, A., Terracciano, L., Al-Kuraya, K. S., Jänicke, F., et al. (2007) · Nature Genetics · doi:10.1038/ng2006 · Cited by 376 · see citing works

Tailoring to RB: tumour suppressor status and therapeutic response

Knudsen, E. S., & Knudsen, K. E. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2401 · Cited by 345 · see citing works

A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer

Laurentiis, M. D., Arpino, G., Massarelli, E., Ruggiero, A., Carlomagno, C., Ciardiello, F., Tortora, G., D’Agostino, D., Caputo, F., Cancello, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2569 · Cited by 340 · see citing works

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

Robertson, J. F. R., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Macpherson, E., Lindemann, J., & Ellis, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1136 · Cited by 310 · see citing works

Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genomePreprint

Bieda, M. C., Xu, X., Singer, M. A., Green, R., & Farnham, P. (2006) · Genome Research · doi:10.1101/gr.4887606 · Cited by 306 · see citing works

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

Thangavel, C., Dean, J. L., Ertel, A., Knudsen, K. E., Aldaz, C. M., Witkiewicz, A. K., Clarke, R., & Knudsen, E. S. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0262 · Cited by 302 · see citing works

Genomic Antagonism between Retinoic Acid and Estrogen Signaling in Breast Cancer

Hua, S., Kittler, R., & White, K. P. (2009) · Cell · doi:10.1016/j.cell.2009.04.043 · Cited by 301 · see citing works

Cooperative interaction between retinoic acid receptor-α and estrogen receptor in breast cancerPreprint

Ross-Innes, C. S., Stark, R., Holmes, K. A., Schmidt, D., Spyrou, C., Russell, R., Massie, C. E., Vowler, S. L., Eldridge, M., & Carroll, J. S. (2010) · Genes & Development · doi:10.1101/gad.552910 · Cited by 260 · see citing works

S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation

Yamnik, R. L., Digilova, A., Davis, D. C., Brodt, Z. N., Murphy, C. J., & Holz, M. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807532200 · Cited by 247 · see citing works

Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells.

Foster, J. S., & Wimalasena, J. (1996) · Molecular Endocrinology · doi:10.1210/mend.10.5.8732680 · Cited by 234 · see citing works

PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer

Crowder, R. J., Phommaly, C., Yu, T., Hoog, J., Luo, J. R., Perou, C. M., Parker, J. S., Miller, M. A., Huntsman, D. D., Li, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4450 · Cited by 218 · see citing works

Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy

Arpino, G., Gutiérrez, C., Weiss, H. L., Rimawi, M. F., Massarweh, S. A., Bharwani, L. D., Placido, S. D., Osborne, C. K., & Schiff, R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk151 · Cited by 187 · see citing works

Estrogen-Independent Proliferation Is Present in Estrogen-ReceptorHER2-Positive Primary Breast Cancer After Neoadjuvant Letrozole

Ellis, M. J., Tao, Y., Young, O., White, S., Proia, A. D., Murray, J., Renshaw, L., Faratian, D., Thomas, J., Dowsett, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3034 · Cited by 172 · see citing works

Transcriptional Activation of E2F1 Gene Expression by 17β-Estradiol in MCF-7 Cells Is Regulated by NF-Y-Sp1/Estrogen Receptor Interactions

Wang, W., Dong, L., Saville, B., & Safe, S. H. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.8.0323 · Cited by 172 · see citing works

Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistancePreprint

Lupien, M., Meyer, C. A., Bailey, S. T., Eeckhoute, J., Cook, J., Westerling, T., Zhang, X., Carroll, J. S., Rhodes, D. R., Liu, X., et al. (2010) · Genes & Development · doi:10.1101/gad.1944810 · Cited by 165 · see citing works

Letrozole Suppresses Plasma Estradiol and Estrone Sulphate More Completely Than Anastrozole in Postmenopausal Women With Breast Cancer

Dixon, J. M., Renshaw, L., Young, O., Murray, J., Macaskill, E. J., McHugh, M., Folkerd, E. J., Cameron, D., A’Hern, R., & Dowsett, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9279 · Cited by 160 · see citing works

Chemical modification of rapamycin: the discovery of SDZ RAD

Sedrani, R. C., Cottens, S., Kallen, J. A., & Schüler, W. (1998) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)00587-9 · Cited by 147 · see citing works

Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation

Chan, C. M. W., Martin, L., Johnston, S. R. D., Ali, S., & Dowsett, M. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00074-2 · Cited by 145 · see citing works

Fulvestrant in Women With Advanced Breast Cancer After Progression on Prior Aromatase Inhibitor Therapy: North Central Cancer Treatment Group Trial N0032

Ingle, J. N., Suman, V. J., Rowland, K. M., Mirchandani, D., Bernath, A. M., Camoriano, J. K., Fishkin, P. A. S., Nikcevich, D. A., & Perez, E. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1053 · Cited by 144 · see citing works

Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells

Bourdeau, V., Deschênes, J., Laperrière, D., Aid, M., White, J. H., & Mader, S. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm945 · Cited by 143 · see citing works

Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death

Tan, P., Bay, B.-H., Yip, G. W., Selvarajan, S., Tan, P., Wu, J., Lee, C.-H., & Li, K.-B. (2004) · Modern Pathology · doi:10.1038/modpathol.3800254 · Cited by 142 · see citing works

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)

Perey, L., Paridaens, R., Hawle, H., Zaman, K., Nolè, F., Wildiers, H., Fiche, M., Dietrich, D., Clément, P., Köberle, D., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl341 · Cited by 136 · see citing works

Additive Antitumor Effect of Aromatase Inhibitor Letrozole and Antiestrogen Fulvestrant in a Postmenopausal Breast Cancer Model

Jelovac, D., Macedo, L. F., Goloubeva, O. G., Handratta, V. D., & Brodie, A. M. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2782 · Cited by 123 · see citing works

Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole

Miller, W. R., Larionov, A. A., Renshaw, L., Anderson, T. J., White, S., Murray, J., Murray, E. L., Hampton, G. M., Walker, J. R., Ho, S., et al. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32820b853a · Cited by 101 · see citing works

Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells

Foster, J. S. (1996) · Molecular Endocrinology · doi:10.1210/me.10.5.488 · Cited by 88 · see citing works

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Angeles, U.S.A.1

Bajetta, E., Zilembo, N., Dowsett, M., Guillevin, L., Leo, A. D., Celio, L., Martinetti, A., Marchianò, A. V., Pozzi, P., Stani, S. C., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00392-x · Cited by 69 · see citing works

Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway

Hoskins, E. E., Gunawardena, R. W., Habash, K. B., Wise-Draper, T. M., Jansen, M., Knudsen, E. S., & Wells, S. I. (2008) · Oncogene · doi:10.1038/onc.2008.121 · Cited by 62 · see citing works

Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer

Ghazoui, Z. F., Buffa, F. M., Dunbier, A. K., Anderson, H., Dexter, T., DETRE, S. I., Salter, J., Smith, I. E., Harris, A. L., & Dowsett, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1704 · Cited by 35 · see citing works

Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials

Voliva, C. F., Pecchi, S., Burger, M. T., Nagel, T., Schnell, C., Fritsch, C. M., Brachmann, S. M., Menezes, D. L. D., Knapp, M. S., Shoemaker, K. R., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-4498 · Cited by 32 · see citing works

Combining Fulvestrant (Faslodex™) with Continued Oestrogen Suppression in Endocrine-sensitive Advanced Breast Cancer: the SoFEA Trial

Dodwell, D. J., Coombes, G., Bliss, J. M., Kilburn, L., & Johnston, S. R. D. (2008) · Clinical Oncology · doi:10.1016/j.clon.2008.02.010 · Cited by 20 · see citing works

Tumor Biomarker Changes Following Pre-Surgical Treatment with 500 mg Fulvestrant Plus Anastrozole Versus 500 mg Fulvestrant Alone and 1 mg Anastrozole Alone.

Robertson, J. F. R., Dixon, J. M., Sibbering, D. M., Jahan, A., Ellis, I. O., Channon, E., Nicholson, R. I., & Gee, J. M. W. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-24 · Cited by 16 · see citing works

A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.

Finn, R., Boér, K., Láng, I., Parikh, R. J., Patel, R., Schmidt, M., Hagenstad, C. T., Lim, H. J., Pintér, T., Amadori, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.tps100 · Cited by 4 · see citing works

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900 · see citing works

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827 · see citing works

The history and future of targeting cyclin-dependent kinases in cancer therapy

Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767 · see citing works

Palbociclib in hormone-receptor-positive advanced breast cancer

Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590 · see citing works

Treating cancer with selective CDK4/6 inhibitors

O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137 · see citing works

Overall survival with ribociclib plus endocrine therapy in breast cancer

Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001 · see citing works

Overcoming Endocrine Resistance in Breast Cancer

Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927 · see citing works

Overall survival with ribociclib plus fulvestrant in advanced breast cancer

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911149 · Cited by 865 · see citing works

The PI3K/AKT Pathway as a Target for Cancer Treatment

Mayer, I. A., & Arteaga, C. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 827 · see citing works

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Hart, L., Campone, M., Petrakova, K., Winer, E. P., Janni, W., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2114663 · Cited by 791 · see citing works

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

Herrera-Abreu, M. T., Palafox, M., Asghar, U. S., Rivas, M. A., Cutts, R. J., García-Murillas, I., Pearson, A., Guzmán, M., Rodríguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 768 · see citing works

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Dieras, V. C., Patt, D. A., Wildiers, H. P. M. W., Hudis, C. A., O’Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 683 · see citing works

The lingering mysteries of metastatic recurrence in breast cancer

Riggio, A. I., Varley, K. E., & Welm, A. L. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01161-4 · Cited by 635 · see citing works

Targeting CDK4 and CDK6 in cancer

Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 555 · see citing works

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Baselga, J. M., Im, S., Iwata, H., Cortés, J., Laurentiis, M. D., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M. J., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 529 · see citing works

CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest

Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 495 · see citing works

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 465 · see citing works

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432 · see citing works

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

Yang, C., Li, Z., Bhatt, T., Dickler, M. N., Giri, D. D., Scaltriti, M., Baselga, J. M., Rosen, N. X., & Chandarlapaty, S. (2016) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 413 · see citing works

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Zotano, Á. G., Mayer, I. A., & Arteaga, C. L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9637-x · Cited by 420 · see citing works

Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment

VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0816 · Cited by 396 · see citing works

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.628690 · Cited by 390 · see citing works

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

Ma, C. X., Gao, F., Luo, J. R., Northfelt, D., Goetz, M. P., Forero, A., Hoog, J., Naughton, M., Ademuyiwa, F. O., Suresh, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3206 · Cited by 360 · see citing works

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer

Mayer, I. A., Abramson, V. G., Formisano, L., Balko, J. M., Estrada, M. V., Sanders, M. E., Juric, D., Solit, D. B., Berger, M. F., Won, H. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0134 · Cited by 320 · see citing works

Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments

Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 332 · see citing works

The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies

Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285 · see citing works

Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors

Tripathy, D., Bardia, A., & Sellers, W. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3157 · Cited by 247 · see citing works

Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs

Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 238 · see citing works

The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap

Ellis, M. J., & Perou, C. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0462 · Cited by 227 · see citing works

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial

Johnston, S. R. D., Puhalla, S., Wheatley, D. A., Ring, A. E., Barry, P. A., Holcombe, C., Boileau, J. F., Provencher, L., Robidoux, A., Rimawi, M. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01624 · Cited by 229 · see citing works

Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications

Gandhi, N. S., & Das, G. M. (2019) · Cells · doi:10.3390/cells8020089 · Cited by 227 · see citing works

The present and future of PI3K inhibitors for cancer therapy

Castel, P., Toska, E., Engelman, J. A., & Scaltriti, M. (2021) · Nature Cancer · doi:10.1038/s43018-021-00218-4 · Cited by 222 · see citing works

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy

Rani, A., Stebbing, J., Giamas, G., & Murphy, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00245 · Cited by 219 · see citing works

Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments

Testa, U., Castelli, G., & Pelosi, E. (2020) · Medical Sciences · doi:10.3390/medsci8010018 · Cited by 238 · see citing works

Advances in the treatment of advanced oestrogen-receptor-positive breast cancer

Turner, N. C., Neven, P., Loibl, S., & Andre, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32419-9 · Cited by 205 · see citing works

Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer

Araki, K., & Miyoshi, Y. (2017) · Breast Cancer · doi:10.1007/s12282-017-0812-x · Cited by 199 · see citing works

Statistical determination of synergy based on Bliss definition of drugs independence

Demidenko, E., & Miller, T. W. (2019) · PLOS ONE · doi:10.1371/journal.pone.0224137 · Cited by 187 · see citing works

Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer

Magnani, L., Stoeck, A., Zhang, X., Lánczky, A., Mirabella, A., Wang, T., Győrffy, B., & Lupien, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219992110 · Cited by 181 · see citing works

Electrostatically Assembled Multilayered Films of Biopolymer Enhanced Nanocapsules for on-Demand Drug Release

Xu, L., Chu, Z., Wang, H., Cai, L., Tu, Z., Liu, H., Zhu, C., Shi, H., Pan, D., Pan, J. H., et al. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00381 · Cited by 180 · see citing works

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

Michaloglou, C., Crafter, C., Siersbæk, R., Delpuech, O., Curwen, J., Carnevalli, L. S., Staniszewska, A. D., Polanska, U. M., Cheraghchi-Bashi, A., Lawson, M., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0537 · Cited by 180 · see citing works

Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Mayer, I. A., Abramson, V. G., Isakoff, S. J., Forero, A., Balko, J. M., Kuba, M. G., Sanders, M. E., Yap, J. T., den Abbeele, A. D. V., Li, Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0518 · Cited by 176 · see citing works

Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck

Simpson, D. R., Mell, L. K., & Cohen, E. E. W. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.11.012 · Cited by 169 · see citing works

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models

Bihani, T., Patel, H., Arlt, H., Tao, N., Jiang, H., Brown, J. L., Purandare, D. M., Hattersley, G., & Garner, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2561 · Cited by 169 · see citing works

At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy

Vasan, N., & Cantley, L. C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00633-1 · Cited by 167 · see citing works

Mechanisms of Genomic Instability in Breast Cancer

Duijf, P. H. G., Nanayakkara, D. M., Nones, K., Srihari, S., Kalimutho, M., & Khanna, K. K. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.04.004 · Cited by 168 · see citing works

Overview of the relevance of PI3K pathway in HR-positive breast cancer

Vasan, N., Toska, E., & Scaltriti, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz281 · Cited by 167 · see citing works

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer

Malorni, L., Piazza, S., Ciani, Y., Guarducci, C., Bonechi, M., Biagioni, C., Hart, C. D., Verardo, R., Leo, A. D., & Migliaccio, I. (2016) · Oncotarget · doi:10.18632/oncotarget.12010 · Cited by 161 · see citing works

Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies

Saatci, Ö., Huynh‐Dam, K., & Şahin, Ö. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02136-5 · Cited by 157 · see citing works

Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells

Caldon, C. E., Sergio, C. M., Kang, J., Muthukaruppan, A., Boersma, M. N., Stone, A. M., Barraclough, J., Lee, C. S., Black, M. A., Miller, L. D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0963 · Cited by 151 · see citing works

Large-Scale Quality Analysis of Published ChIP-seq Data

Marinov, G. K., Kundaje, A. B., Park, P. J., & Wold, B. J. (2013) · G3 Genes Genomes Genetics · doi:10.1534/g3.113.008680 · Cited by 146 · see citing works

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

Yip, P. Y. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.01.04 · Cited by 144 · see citing works

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways

Miller, T. W., & Hosford, S. R. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52762 · Cited by 145 · see citing works

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective

Hernándo, C., Ortega-Morillo, B., Tapia, M., Moragón, S., Martínez, M. T., Eroles, P., Garrido‐Cano, I., Adam‐Artigues, A., Lluch, A. M., Bermejo, B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157812 · Cited by 139 · see citing works

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer

Formisano, L., Stauffer, K. M., Young, C. D., Bhola, N. E., Zotano, Á. G., Jansen, V. M., Estrada, M. M., Hutchinson, K. E., Giltnane, J. M., Schwarz, L. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1232 · Cited by 133 · see citing works

Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives

Marra, A., Chandarlapaty, S., & Modi, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00849-9 · Cited by 130 · see citing works

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions

Witkiewicz, A. K., & Knudsen, E. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3652 · Cited by 126 · see citing works

Genomic profiling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., Nixon, M. J., Du, L., Sanchez, V. M., Ericsson, P. I. G., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7993 · Cited by 126 · see citing works

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance

Montaudon, É., Nikitorowicz-Buniak, J., Sourd, L., Morisset, L., Botty, R. E., Huguet, L., Dahmani, A., Painsec, P., Némati, F., Vacher, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17697-1 · Cited by 122 · see citing works

HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models

Whitesell, L. J., Santagata, S., Mendillo, M. L., Lin, N., Proia, D. A., & Lindquist, S. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421323111 · Cited by 119 · see citing works

Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role

Lloyd, M. R., Wander, S. A., Hamilton, E. P., Razavi, P., & Bardia, A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221113694 · Cited by 118 · see citing works

Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma

Beck, J. T., Ismail, A., & Tolomeo, C. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.006 · Cited by 117 · see citing works

Are all cyclin-dependent kinases 4/6 inhibitors created equal?

Marra, A., & Curigliano, G. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0121-y · Cited by 118 · see citing works

Targeting cell cycle and hormone receptor pathways in cancer

Comstock, C. E. S., Augello, M. A., Goodwin, J. F., de Leeuw, R., Schiewer, M. J., Ostrander, W. F., Burkhart, R. A., McClendon, A. K., McCue, P. A., Trabulsi, E. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.83 · Cited by 114 · see citing works

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer

Traina, T. A., Cadoo, K. A., & Gucalp, A. (2014) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s46725 · Cited by 111 · see citing works

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

Malorni, L., Curigliano, G., Minisini, A. M., Cinieri, S., Tondini, C. A., D’Hollander, K., Arpino, G., Bernardo, A., Martignetti, A., Criscitiello, C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy214 · Cited by 110 · see citing works

Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer

Rocca, A., Farolfi, A., Bravaccini, S., Schirone, A., & Amadori, D. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.870555 · Cited by 108 · see citing works

Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

O’Brien, N. A., Conklin, D. F., Beckmann, R. P., Luo, T., Chau, K., Thomas, J. D., Nulty, A. M., Marchal, C. C., Kalous, O., von Euw, E., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0290 · Cited by 108 · see citing works

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

Croessmann, S., Formisano, L., Kinch, L. N., Ericsson, P. I. G., Sudhan, D. R., Nagy, R. J., Mathew, A., Bernicker, E., Cristofanilli, M., He, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1544 · Cited by 107 · see citing works

Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets

Paul, M. R., Pan, T.-C., Pant, D. K., Shih, N. N. C., Chen, Y., Harvey, K. L., Solomon, A. C., Lieberman, D. B., Morrissette, J. J. D., Soucier-Ernst, D., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129941 · Cited by 105 · see citing works

Breast cancer: Current and future endocrine therapies

Palmieri, C., Patten, D. K., Januszewski, A. P., Zucchini, G., & Howell, S. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.001 · Cited by 100 · see citing works

Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer

Du, T., Sikora, M. J., Levine, K. M., Tasdemir, N., Riggins, R. B., Wendell, S. G., Houten, B. V., & Oesterreich, S. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1041-8 · Cited by 99 · see citing works

Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS

Dey, P., Barros, R. P. A., Warner, M. N., Ström, A., & Gustafsson, J.-Α. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0150 · Cited by 98 · see citing works

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

Ma, C. X., Luo, J. R., Naughton, M., Ademuyiwa, F. O., Suresh, R., Griffith, M., Griffith, O. L., Skidmore, Z. L., Spies, N. C., Ramu, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1745 · Cited by 96 · see citing works

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival

Miglietta, F., Bottosso, M., Griguolo, G., Dieci, M. V., & Guarneri, V. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100409 · Cited by 99 · see citing works

Approaches to modernize the combination drug development paradigm

Day, D., & Siu, L. L. (2016) · Genome Medicine · doi:10.1186/s13073-016-0369-x · Cited by 94 · see citing works

Transcription and Translation Inhibitors in Cancer Treatment

Laham-Karam, N., Pinto, G., Poso, A., & Kokkonen, P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00276 · Cited by 88 · see citing works

Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells

Hu, Y., Guo, R., Wei, J., Zhou, Y., Ji, W., Liu, J., Zhi, X., & Zhang, J. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.363 · Cited by 92 · see citing works

The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer

Schoninger, S., & Blain, S. W. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0253 · Cited by 91 · see citing works

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Turner, N. C., Dent, R. A., O’Shaughnessy, J., Kim, S., Isakoff, S. J., Barrios, C. H., Saji, S., Bondarenko, I., Nowecki, Z. I., Lian, Q., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06450-x · Cited by 92 · see citing works

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities

Pancholi, S., Ribas, R., Simigdala, N., Schuster, E. F., Nikitorowicz-Buniak, J., Ressa, A., Gao, Q., Leal, M. F., Bhamra, A., Thornhill, A. M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1284-6 · Cited by 91 · see citing works

Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer

Yuan, Y., Lee, J. S., Yost, S. E., Frankel, P. H., Ruel, C., Egelston, C. A., Guo, W., Padam, S., Tang, A., Martínez, N., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.035 · Cited by 91 · see citing works

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

Al-Qasem, A. J., Alves, C. L., Ehmsen, S., Tuttolomondo, M., Terp, M. G., Johansen, L. E., Vever, H., Hoeg, L. V. A., Eliáš, D., Bak, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00311-6 · Cited by 92 · see citing works

HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles

Sammons, S. L., Topping, D. L., & Blackwell, K. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009617666170330120452 · Cited by 86 · see citing works

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Alves, C. L., Ehmsen, S., Terp, M. G., Portman, N., Tuttolomondo, M., Gammelgaard, O. L., Hundebøl, M. F., Kaminska, K. K., Johansen, L. E., Bak, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25422-9 · Cited by 86 · see citing works

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer

Anderson, E. J., Mollon, L. E., Dean, J. L., Warholak, T. L., Aizer, A. A., Platt, E., Tang, D. H., & Davis, L. E. (2020) · International Journal of Breast Cancer · doi:10.1155/2020/3759179 · Cited by 82 · see citing works

Genome-wide activity of unliganded estrogen receptor-α in breast cancer cells

Caizzi, L., Ferrero, G., Cutrupi, S., Cordero, F., Ballaré, C., Miano, V., Reineri, S., Ricci, L., Friard, O., Testori, A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315445111 · Cited by 81 · see citing works

Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway

Qin, G., Xu, F., Qin, T., Zheng, Q., Shi, D., Xia, W., Tian, Y., Tang, Y., Wang, J., Xiao, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5993 · Cited by 79 · see citing works

Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects

Arnesen, S., Blanchard, Z., Williams, M. M., Berrett, K. C., Li, Z., Oesterreich, S., Richer, J. K., & Gertz, J. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1171 · Cited by 79 · see citing works

CDCA5, Transcribed by E2F1, Promotes Oncogenesis by Enhancing Cell Proliferation and Inhibiting Apoptosis via the AKT Pathway in Hepatocellular Carcinoma

Chen, H., Chen, J., Zhao, L., Song, W., Xuan, Z., Chen, J., Li, Z., Song, P., Hong, L., Song, P., et al. (2019) · Journal of Cancer · doi:10.7150/jca.28809 · Cited by 78 · see citing works

Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

Patel, H., Tao, N., Lee, K.-M., Huerta-Rosario, M., Arlt, H., Mullarkey, T. L., Troy, S. M., Arteaga, C. L., & Bihani, T. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1230-0 · Cited by 78 · see citing works

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Ballinger, T. J., Meier, J. B., & Jansen, V. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00308 · Cited by 76 · see citing works

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib

Raspé, E., Coulonval, K., Pita, J. M. G., Paternot, S., Rothé, F., Twyffels, L., Brohée, S., Craciun, L., Larsimont, D., Kruys, V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607084 · Cited by 74 · see citing works

Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer

Pathiraja, T. N., Nayak, S. R., Xi, Y., Jiang, S., Garee, J. P., Edwards, D. P., Lee, A. V., Chen, J., Shea, M. J., Santen, R. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008326 · Cited by 74 · see citing works

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer

Alves, C. L., Eliáš, D., Lyng, M., Bak, M., Kirkegaard, T., Lykkesfeldt, A. E., & Ditzel, H. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1984 · Cited by 69 · see citing works

Overexpression of E2F mRNAs Associated with Gastric Cancer Progression Identified by the Transcription Factor and miRNA Co-Regulatory Network Analysis

Zhang, X., Ni, Z., Duan, Z., Xin, Z., Wang, H., Tan, J., Wang, G., & Fan, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116979 · Cited by 68 · see citing works

CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives

Roberto, M., Astone, A., Botticelli, A., Carbognin, L., Cassano, A., D’Auria, G., Fabbri, A., Fabi, A., Gamucci, T., Krasniqi, E., et al. (2021) · Cancers · doi:10.3390/cancers13020332 · Cited by 65 · see citing works

Tumour selective targeting of cell cycle kinases for cancer treatment

Aarts, M., Linardopoulos, S., & Turner, N. C. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.03.012 · Cited by 67 · see citing works

An update on the medical management of breast cancer

Yeo, B. J., Turner, N. C., & Jones, A. L. (2014) · BMJ · doi:10.1136/bmj.g3608 · Cited by 63 · see citing works

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

Campone, M., Im, S., Iwata, H., Clemons, M. J., Ito, Y., Awada, A. H., Chia, S., Jagiełło-Gruszfeld, A., Pistilli, B., Tseng, L., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.002 · Cited by 62 · see citing works

New approaches for improving outcomes in breast cancer in Europe

Leo, A. D., Curigliano, G., Dieras, V. C., Malorni, L., Sotiriou, C. P., Swanton, C., Thompson, A. M., Tutt, A. N. J., & Piccart, M. J. (2015) · The Breast · doi:10.1016/j.breast.2015.03.001 · Cited by 60 · see citing works

Abstract PD05-05: Hormone-Independent Breast Cancer Cells Maintain an ERα — Dependent, E2F-Directed Transcriptional Program

Miller, T., Fox, E., Balko, J. M., Jiang, A., Smith, R. N., Manning, H. C., Ye, F., Shyr, Y., & Arteaga, C. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-pd05-05

Abstract 835: Estrogen receptor expression and ER dependent breast tumor growth are dependent on translation initiation factor EIF4A

Boyer, J. A., Dorso, M. A., Amor, C., Reiter, J., Xu, J., de Stanchina, E., Wendel, H., Chandarlapaty, S., & Rosen, N. X. (2022) · Cancer Research · doi:10.1158/1538-7445.am2022-835

Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer

Bhola, N. E., Jansen, V. M., Bafna, S., Giltnane, J. M., Balko, J. M., Estrada, M. V., Meszoely, I. M., Mayer, I. A., Abramson, V. G., Ye, F., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2475 · Cited by 60 · see citing works

Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation

Fox, E. M., Kuba, M. G., Miller, T. W., Davies, B. R., & Arteaga, C. L. (2013) · Breast Cancer Research · doi:10.1186/bcr3449 · Cited by 90 · see citing works

Abstract 4825: Inhibition of AKT abrogates resistance to endocrine therapy in estrogen receptor positive breast cancer

Fox, E. M., Davies, B. R., & Arteaga, C. L. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-4825